# Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD

> **NCT06475781** · PHASE2 · RECRUITING · sponsor: **Foresee Pharmaceuticals Co., Ltd.** · enrollment: 126 (estimated)

## Conditions studied

- Group 3 Pulmonary Hypertension

## Interventions

- **DRUG:** Mirivadelgat
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT06475781
- **Lead sponsor:** Foresee Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-01
- **Primary completion:** 2028-06
- **Final completion:** 2028-08
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2025-10-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06475781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06475781, "Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06475781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*